Hideki Suganami
Tokyo University of Science
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Hideki Suganami.
JAMA Ophthalmology | 2015
Hidenobu Tanihara; Toshihiro Inoue; Tetsuya Yamamoto; Yasuaki Kuwayama; Haruki Abe; Hideki Suganami; Makoto Araie
IMPORTANCE Ripasudil hydrochloride hydrate (K-115), a novel rho kinase inhibitor, provides statistically significant intraocular pressure (IOP)-lowering effects and has a tolerable safety profile. However, no studies have evaluated ripasudil combined with β-blockers and prostaglandin analogues. OBJECTIVE To evaluate the additive IOP-lowering effects and the safety of ripasudil, 0.4%, combined with timolol, 0.5%, or latanoprost, 0.005%, in patients with primary open-angle glaucoma or ocular hypertension. DESIGN, SETTING, AND PARTICIPANTS We conducted 2, multicenter, randomized, double-masked, parallel group comparison studies of ripasudil-timolol and ripasudil-latanoprost in 29 and 36 Japanese clinical centers, respectively. Analyses were performed on an intention-treat-treat basis. After appropriate run-in periods with timolol or latanoprost, 208 and 205 patients whose IOP levels were 18 mm Hg or higher were enrolled in the ripasudil-timolol and ripasudil-latanoprost groups, respectively. Enrollment began December 1, 2011, and follow-up was completed on September 7, 2012, in the ripasudil-timolol study. Enrollment began December 1, 2011, and follow-up was completed on September 27, 2012, in the ripasudil-latanoprost study. INTERVENTIONS Patients were subdivided into 2 groups in each study and were treated with ripasudil or placebo twice daily for 8 weeks. MAIN OUTCOMES AND MEASURES The IOP reductions in the ripasudil and placebo groups were analyzed with a repeated-measures analysis of variance model at weeks 4, 6, and 8, at trough (before instillation [9 am]) and peak (2 hours after instillation [11 am]) levels. RESULTS In the ripasudil-timolol study, the mean IOP reductions from baseline in the ripasudil and placebo groups were -2.4 and -1.5 mm Hg at 9 am for a difference of 0.9 mm Hg (95% CI, 0.4-1.3 mm Hg; P < .001) and -2.9 and -1.3 mm Hg at 11 am for a difference of 1.6 mm Hg (95% CI, 1.1-2.1 mm Hg; P < .001), respectively. In the ripasudil-latanoprost study, those IOP reductions were -2.2 and -1.8 mm Hg at 9 am for a difference of 0.4 mm Hg (95% CI, -0.0 to 0.9 mm Hg; P = .06) and -3.2 and -1.8 mm Hg at 11 am for a difference of 1.4 mm Hg (95% CI, 0.9-1.9 mm Hg; P < .001), respectively. The most frequently reported adverse event was conjunctival hyperemia, which was mild and in most cases resolved without treatment before the next instillation. CONCLUSIONS AND RELEVANCE These clinical trials found additive IOP-lowering effects of ripasudil from placebo at trough and peak levels in combination with timolol and at peak level in combination with latanoprost. However, a definitive difference in the addition of placebo to latanoprost was not identified in the trough level. TRIAL REGISTRATION clinicaltrials.jp Identifiers: JAPIC111700 and JAPIC111701.
Acta Ophthalmologica | 2015
Hidenobu Tanihara; Toshihiro Inoue; Tetsuya Yamamoto; Yasuaki Kuwayama; Haruki Abe; Hideki Suganami; Makoto Araie
To investigate the intra‐ocular pressure (IOP)‐lowering effects of a selective Rho kinase inhibitor, ripasudil (K‐115), over 24 hr in patients with primary open‐angle glaucoma (POAG) or ocular hypertension (OHT).
Acta Ophthalmologica | 2016
Hidenobu Tanihara; Toshihiro Inoue; Tetsuya Yamamoto; Yasuaki Kuwayama; Haruki Abe; Atsuki Fukushima; Hideki Suganami; Makoto Araie
To investigate the intra‐ocular pressure (IOP)‐lowering effects and safety of 0.4% ripasudil (K‐115), a Rho kinase inhibitor, twice daily for 52 weeks, in patients with open‐angle glaucoma or ocular hypertension (OHT).
Journal of Human Genetics | 2004
Yasunori Sato; Hideki Suganami; Chikuma Hamada; Isao Yoshimura; Teruhiko Yoshida; Kimio Yoshimura
AbstractA genome-wide linkage equilibrium mapping is an emerging strategy to identify risk-modifying genes for common diseases, despite unsettled controversies upon many aspects, including its premises, designs, marker choices and cost benefits. One large-scale attempt in Japan aims to identify disease-associated single nucleotide polymorphisms (SNPs) for five diseases among the Japanese population: Alzheimer′s disease, gastric cancer, diabetes, hypertension and asthma. Following an initial screening of c.a. 100,000 SNPs on 940 subjects (five diseases × 188 patients) to select about 2,000 SNPs, we compared which subsequent screening design is more appropriate, and an additional one or two screens to further narrow down any disease-associated SNPs within a fixed total volume of 15,040,000 typings (2,000 SNPs × five diseases × 1,504 subjects, comprising 752 cases and 752 controls). We employed a Monte Carlo simulation to evaluate the probability of identifying truly disease-associated SNPs. The results suggest the single additional stage design (i.e., total two-stage design including the initial screening of 100,000 SNPs) was more practicable for the simple reason that the gain in probability is considered insufficient relative to an associated increase in study complexity in the three-stage design.
Journal of Human Genetics | 2006
Yasunori Sato; Hideki Suganami; Chikuma Hamada; Isao Yoshimura; Hiromi Sakamoto; Teruhiko Yoshida; Kimio Yoshimura
AbstractIn single nucleotide polymorphism (SNP) data analysis, the allelic odds ratio and its confidence interval (CI) are usually used to evaluate the association between disease and alleles at each SNP. The usual formula for calculating the CI of the allelic odds ratio based on the Hardy-Weinberg equilibrium (HWE) may, however, lead to errors beyond the control assured by the nominal confidence level if HWE is not true. We therefore present a generalized formula for CI that does not assume HWE. CIs calculated by this generalized formula are likely to be wider than those by the usual method if the Hardy-Weinberg disequilibrium (HWD) is toward a relative deficiency of the heterozygotes (fixation index greater than 0), whereas they are likely to be narrower if HWD is toward a relative excess of the heterozygotes (fixation index less than 0). A simulation experiment to examine the influence of the generalization was performed for the case where 2% of SNPs had a fixation index greater than 0. The result revealed that the generalized method slightly decreased the mean number of falsely detected SNPs.
PLOS ONE | 2015
Hiroko Nakagawa; Noriko Koizumi; Naoki Okumura; Hideki Suganami; Shigeru Kinoshita
Purpose To investigate the effect and safety of a selective Rho kinase inhibitor, ripasudil 0.4% eye drops, on corneal endothelial cells of healthy subjects. Design Prospective, interventional case series. Methods In this study, 6 healthy subjects were administered ripasudil 0.4% in the right eye twice daily for 1 week. Morphological changes and corneal endothelial cell density were examined by noncontact and contact specular microscopy. Central corneal thickness and corneal volume of 5 mm-diameter area of center cornea were analyzed by Pentacam Scheimpflug topography. All the above measurements were conducted in both eyes before administration, 1.5 and 6 hours after the initial administration on day 0; and in the same manner after the final administration on day 7. Results By noncontact specular microscopy, indistinct cell borders with pseudo guttae were observed, but by contact specular microscopy, morphological changes of corneal endothelial cells were mild and pseudo guttae was not observed after single and repeated administration of ripasudil in all subjects. These changes resolved prior to the next administration, and corneal endothelial cell density, central corneal thickness and corneal volume were not changed throughout the study period. Conclusion Transient morphological changes of corneal endothelial cells such as indistinct cell borders with pseudo guttae were observed by noncontact specular microscopy in healthy subjects after ripasudil administration. Corneal edema was not observed and corneal endothelial cell density did not decrease after 1 week repetitive administration. These morphological changes were reversible and corneal endothelial cell morphology returned to normal prior to the next administration. Trial Registration JAPIC Clinical Trials Information 142705
Journal of Forensic and Legal Medicine | 2015
Noboru Ishikawa; Hideki Suganami; Atsushi Nishida; Daisuke Miyamori; Yasuhiro Kakiuchi; Naotake Yamada; Kim Wook-Cheol; Toshikazu Kubo; Hiroshi Ikegaya
In the field of Forensic Medicine the number of unidentified cadavers has increased due to natural disasters and international terrorism. The age estimation is very important for identification of the victims. The degree of sagittal closure is one of such age estimation methods. However it is not widely accepted as a reliable method for age estimation. In this study, we have examined whether measuring impedance value (z-values) of the sagittal suture of the skull is related to the age in men and women and discussed the possibility to use bone impedance for age estimation. Bone impedance values increased with aging and decreased after the age of 64.5. Then we compared age estimation through the conventional visual method and the proposed bone impedance measurement technique. It is suggested that the bone impedance measuring technique may be of value to forensic science as a method of age estimation.
Microbes and Infection | 2004
Huai-Ying Zheng; Pengyun Zhao; Hideki Suganami; Yasuo Ohasi; Hiroshi Ikegaya; Jung-Chul Kim; Chie Sugimoto; Tomokazu Takasaka; Tadaichi Kitamura; Yoshiaki Yogo
American Journal of Physical Anthropology | 2005
Hiroshi Ikegaya; Huai-Ying Zheng; Pekka Saukko; Leena Varesmaa-Korhonen; Tapani Hovi; Timo Vesikari; Hideki Suganami; Tomokazu Takasaka; Chie Sugimoto; Yasuo Ohasi; Tadaichi Kitamura; Yoshiaki Yogo
Canadian Journal of Criminology and Criminal Justice | 2008
Hiroshi Ikegaya; Hideki Suganami